Last updated: February 25, 2026
What is NDC 00456-1500?
NDC 00456-1500 is a specific formulation of insulin glargine, a long-acting insulin used in diabetes management. Manufactured by Sanofi, it is marketed under the brand name Lantus and its biosimilar versions.
Market Size and Trends
Global Diabetes Market Overview
The insulin segment accounts for approximately $25 billion annually worldwide. The demand for long-acting insulins like insulin glargine has increased due to rising prevalence of type 1 and type 2 diabetes. The global diabetes population exceeds 537 million, projected to reach over 700 million by 2045 [1].
Specific Market Drivers
- Prevalence of Diabetes: Growing incidence in North America, Europe, and Asia-Pacific.
- Treatment Adoption: Shift toward biosimilars to reduce costs.
- Regulatory Landscape: Favorable policies for biosimilar entry in key regions.
- Patient Preference: Preference for once-daily long-acting insulins with stable pharmacokinetics.
Market Segmentation
| Segment |
Share |
Key Players |
Notable Products |
| Originator (Lantus) |
60% |
Sanofi |
Lantus, Toujeo |
| Biosimilars |
40% |
Mylan, Biocon, uusanol |
Basalog, Semglee |
Patent and Competitive Dynamics
Lantus’s patent expired in Europe in 2015 and in the U.S. in 2015, opening the market for biosimilars. Biosimilar sales have gained approximately 15-20% CAGR since 2018, capturing market share from originators.
Pricing Analysis
Current Pricing
| Product |
List Price (U.S.) |
Discounted Price |
Average Dose Cost (per month) |
| Lantus (original) |
$255 per 10 mL vial |
$240* |
~$280 |
| Semglee (biosimilar) |
$130 per 10 mL vial |
$125* |
~$145 |
*Prices are publicly available estimates; actual prices vary by healthcare provider, payer, and geographic region.
Historical Price Trends
- 2010-2015: Originator prices increased by approximately 8% annually.
- 2016-2018: Introduction of biosimilars led to price reductions of 20-30%, with biosimilar options priced around $120-$130.
- 2020 onward: Pricing remains relatively stable; biosimilar market share increases are exerting downward pressure.
Future Price Projections (Next 5 Years)
| Scenario |
Market Penetration |
Expected Price for Biosimilars |
Key Factors |
| Conservative |
50% biosimilar market share |
$120 - $130 |
Regulatory hurdles, supply chain |
| Optimistic |
70% biosimilar market share |
$110 - $125 |
Greater biosimilar acceptance, patent expiries |
| Pessimistic |
30% biosimilar market share |
$125 - $135 |
Brand loyalty, pricing policies |
Pricing Influencing Factors
- Regulatory Approvals: Speed and scope of biosimilar approvals.
- Reimbursement Policies: Governmental and insurer policies favoring biosimilars.
- Manufacturing Costs: Potential reductions with biosimilar production scale.
- Brand Loyalty: Physicians and patients may prefer established brands.
Market Opportunities and Risks
Opportunities
- Expansion into emerging markets with high diabetes prevalence.
- Development of biosimilars with improved delivery devices.
- Strategic partnerships for biosimilar commercialization.
Risks
- Entrenched preference for originator brands.
- Healthcare policy shifts restricting biosimilar adoption.
- Patent litigations delaying biosimilar entry.
Summary of Key Data Points
- Total global insulin market: $25 billion (2022).
- Insulin glargine (including NDC 00456-1500): Major segment within long-acting insulins.
- Biosimilar sales CAGR: 15-20% since 2018.
- Price reduction since biosimilar introduction: 20-30%.
- Estimated biosimilar market share by 2028: 50-70%.
Key Takeaways
- NDC 00456-1500 is a long-acting insulin with significant market presence.
- Biosimilar competition is increasing, driving prices downward.
- Pricing in key markets is projected to stabilize around $110-$130 per vial.
- Market expansion in emerging regions presents growth opportunities.
- Regulatory, reimbursement, and competitive dynamics heavily influence future pricing trajectories.
FAQs
1. When did the patent for Lantus expire in the U.S.?
The patent expired in 2015, enabling biosimilar entrants [2].
2. Are biosimilars interchangeable with the originator insulin?
Interchangeability depends on regional regulatory designations; in some markets, biosimilars are not automatically interchangeable.
3. What factors can accelerate biosimilar adoption?
Favorable reimbursement policies, physician prescribing habits, and patient acceptance.
4. How do manufacturing costs impact biosimilar pricing?
Lower production costs due to scale and streamlined processes can support reduced prices.
5. Will originator brands maintain pricing power?
Limited, as biosimilar competition generally exerts downward pressure on prices over time.
References
[1] International Diabetes Federation (IDF). (2022). IDF Diabetes Atlas, 10th edition.
[2] U.S. Food and Drug Administration. (2015). Approved Biologic License Applications for Insulin Products.
